The Comité économique des produits de santé (CEPS) issued its definitive Rapport d'activité 2024 (2024 Activity Report) on 17 December 2025. Virginie Beaumeunier, President of the Comité économique des produits de santé, confirmed that the authority achieved savings of €856 million through targeted medicine price reductions. These figures highlight a period of intensive fiscal regulation as total reimbursable sales in France grew by 6.7% to reach €37.2 billion.
The report notes that conventional rebates, provided by manufacturers in exchange for maintained public list prices, reached nearly €8 billion in 2024. Additionally, the safeguard clause (clause de sauvegarde) was triggered for the fourth year running, as pharmaceutical turnover exceeded the established ‘Amount M’ threshold. This resulted in a gross financial contribution of €1.712 billion from the sector.
New regulatory measures introduced during the year include the creation of a registry for hybrid medicine groups to encourage pharmacy substitution. The authority also formalised a doctrine for pricing combination therapies based on total treatment costs. Data show that the median time for listing new patented products in the retail sector was 175 days, while hospital-only listings took 316 days.
Efforts to reduce processing times will continue into 2026, alongside more frequent reviews of price and reimbursement levels. Manufacturers face an environment defined by increasingly systematic rebate triggers and stringent cost-containment measures. Enhanced scrutiny of clinical relevance and budget sustainability will govern future market entries, as the authority seeks to balance patient access with the long-term solvency of the national health insurance system.
Source: Comité économique des produits de santé (CEPS)
Link: CEPS 2024 Activity Report
Date: 17 December 2025